Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276813 | 0.84 | GRM2 (0.40) | GRM2SLC9A1ALDH1A1 | |
| SCHEMBL5288008 | 0.82 | GRM2 (0.36) | GRM2SLC9A1NPC1 | |
| SCHEMBL5275433 | 0.82 | GRM2 (0.36) | GRM2SLC9A1NPC1 | |
| SCHEMBL5282185 | 0.81 | GRM2 (0.43) | GRM2SLC9A1 | |
| SCHEMBL5276766 | 0.79 | GRM2 (0.34) | GRM2SLC9A1NPC1 | |
| SCHEMBL5275163 | 0.79 | GRM2 (0.34) | GRM2SLC9A1NPC1 | |
| SCHEMBL5276361 | 0.78 | SLC9A1 (0.43) | GRM2SLC9A1ALDH1A1 | |
| SCHEMBL5282137 | 0.77 | SLC9A1 (0.34) | GRM2SLC9A1NPC1ALDH1A1 | |
| SCHEMBL5273066 | 0.77 | SLC9A1 (0.34) | GRM2SLC9A1NPC1ALDH1A1 | |
| SCHEMBL5278450 | 0.75 | SLC9A1 (0.33) | GRM2SLC9A1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | GRM2 567/4885SLC9A1 4685/4885NPC1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.